Question-and-Answer Session
Operator
(Operator Instructions) Our first question comes from the line of John Newman with Oppenheimer.
John Newman - Oppenheimer
Thanks for taking the question. On Cinryze could you tell us what percentage of Cinryze patients currently on drug came from previous clinical trials including the extension trials? Thanks.
Dan Soland
It’s a good question. And we have a good number of patients on drug that are from the clinical trial. But we also have a fair number of that are new patients. The exact numbers we are not planning to disclose today.
John Newman - Oppenheimer
Okay. And you mentioned that the reimbursement is going well for Cinryze. Could you talk about the number that you mentioned, I think was 116. What is that in terms of sort of the total percentage of insurers that you're dealing with now? Is it the bulk of them or is it a sort of mid-level percentage?
Dan Soland
We’re extremely pleased with having 116 insurers now reimbursing for at least one patient each and I can tell you that we think it is probably a very high percentage of the overall number of plans.
Operator
Our next question comes from the line of Joel Sendek with Lazard Capital Markets.
Joel Sendek - Lazard Capital Markets
Hi. Thanks a lot. Also a Cinryze question can you give us a sense of inter-quarter trends in patients and any insight on doses per patient?
Vincent Milano
Joel, I just have to clarify your question, when you say inter-quarter what do you mean?
Joel Sendek - Lazard Capital Markets
I mean, January, February, March and, so far in April what the value like doubling from one months to the next? Is their initial fall list just kind of, at the flat line I mean that sort of thing?
Vincent Milano
So, let me, we won’t comment on April but as far as the first quarter goes as we have discussed in the past this has been a moment of building situation because of the time it takes get reimbursement. So, we have more patients in March than we do in February than we have in January very clearly. And more doses delivered and on this dose question we are not going to give doses per patient at this point.
If we can give factual number but it would not necessary be predictive of the future and we want to guard against the incorrect conclusions being drawn by the math that you could do there. So, that's why we are just sharing with the investment community today, that doses that we delivered to the patients during the quarter, which again we are extremely excited about the progress we have made with $6.7 million of sales and over 2000 doses delivered to patients during the first quarter.
- To read the full transcript on Seeking Alpha, click here »
